TRIM21 is a novel regulator of Par-4 in colon and pancreatic cancer cells

References

• Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute.
   Google Scholar
• Pai SG, Fuloria J. Novel therapeutic agents in the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8:99-104; PMID:26798440; http://dx.doi.org/10.4251/wjgo.v8.i1.99
   PubMedGoogle Scholar
• Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M. Is metastatic pancreatic cancer an untargetable malignancy? World J Gastrointest Oncol 2016; 8:297-304; PMID:26989465; http://dx.doi.org/10.4251/wjgo.v8.i3.297
   PubMedGoogle Scholar
• Sells SF, Wood DP, Jr., Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S, Rangnekar VM. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994; 5:457-66; PMID: 8043520
   PubMedGoogle Scholar
• Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 2005; 25:1146-61; PMID:15657440; http://dx.doi.org/10.1128/MCB.25.3.1146-1161.2005
   PubMed Web of Science ®Google Scholar
• Irby RB, Kline CL. Par-4 as a potential target for cancer threapy. Exp Opin Therap Targets 2013; 1:77-87; PMID:23062118; http://dx.doi.org/10.1517/14728222.2013.731047
   Web of Science ®Google Scholar
• Lucas T, Pratscher B, Krishnan S, Fink D, Gunsberg P, Wolschek M, Wacheck V, Muster T, Romirer I, Wolff K, et al. Differential expression levels of Par-4 in melanoma. Melanoma Res 2001; 11:379-83; PMID:11479426; http://dx.doi.org/10.1097/00008390-200108000-00008
   PubMed Web of Science ®Google Scholar
• Boehrer S, Chow KU, Beske F, Kukoc-Zivojnov N, Puccetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer D, Mitrou PS, et al. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 2002; 62:1768-75; PMID:11912153
   PubMed Web of Science ®Google Scholar
• Kline CL, Shanmugavelandy SS, Kester M, Irby RB. Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther 2009; 8:1831-7; PMID:19729995; http://dx.doi.org/10.4161/cbt.8.19.9592
   PubMed Web of Science ®Google Scholar
• Sharma AK, Kline CL, Berg A, Amin S, Irby RB. The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model. Clin Cancer Res 2011; 17:4474-83; PMID:21555373; http://dx.doi.org/10.1158/1078-0432.CCR-10-2370
   PubMed Web of Science ®Google Scholar
• Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3′ diindolylmethane (DIM). Pharm Res 2008; 25:2117-24; PMID:18427961; http://dx.doi.org/10.1007/s11095-008-9581-8
   PubMed Web of Science ®Google Scholar
• Azmi AS, Wang Z, Burikhanov R, Rangnekar VM, Wang G, Chen J, Wang S, Sarkar FH, Mohammad RM. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther 2008; 7:2884-93; PMID:18790769; http://dx.doi.org/10.1158/1535-7163.MCT-08-0438
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001; 61:7255-63; PMID:11585763.
   PubMed Web of Science ®Google Scholar
• Camandola S, Mattson MP. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression. J Neurosci Res 2000; 61:134-9; PMID:10878585; http://dx.doi.org/10.1002/1097-4547(20000715)61:2%3c134::AID-JNR3%3e3.0.CO;2-P
   PubMed Web of Science ®Google Scholar
• Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 2003; 278:19995-20005; PMID:12644474; http://dx.doi.org/10.1074/jbc.M205865200
   PubMed Web of Science ®Google Scholar
• Chendil D, Das A, Dey S, Mohiuddin M, Ahmed MM. Par-4, a pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 2002; 1:152-60; PMID:12170775; http://dx.doi.org/10.4161/cbt.61
   PubMed Web of Science ®Google Scholar
• Qiu G, Ahmed M, Sells SF, Mohiuddin M, Weinstein MH, Rangnekar VM. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 1999; 18:623-31; PMID:9989812; http://dx.doi.org/10.1038/sj.onc.1202344
   PubMed Web of Science ®Google Scholar
• Bergmann M, Kukoc-Zivojnov N, Chow KU, Trepohl B, Hoelzer D, Weidmann E, Mitrou PS, Boehrer S. Prostate apoptosis response gene-4 sensitizes neoplastic lymphocytes to CD95-induced apoptosis. Annals of hematology 2004; 83:646-53; PMID:15316756; http//dx.doi.org/10.1007/s00277-004-0922-3
   PubMed Web of Science ®Google Scholar
• Lee TJ, Jang JH, Noh HJ, Park EJ, Choi KS, Kwon TK. Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells. J Cell Biochem 2010; 109:885-95; PMID:20127709; http://dx.doi.org/10.1002/jcb.22504
   PubMed Web of Science ®Google Scholar
• Thayyullathil F, Rahman A, Pallichankandy S, Patel M, Galadari S. ROS-dependent prostate apoptosis response-4 (Par-4) up-regulation and ceramide generation are the prime signaling events associated with curcumin-induced autophagic cell death in human malignant glioma. FEBS open bio 2014; 4:763-76; PMID:25349781; http://dx.doi.org/10.1016/j.fob.2014.08.005
   PubMed Web of Science ®Google Scholar
• Zhang Z, DuBois RN. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 2000; 118:1012-7; PMID:10833474; http://dx.doi.org/10.1016/S0016-5085(00)70352-0
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res 2007; 67:246-53; PMID:17185378; http://dx.doi.org/10.1158/0008-5472.CAN-06-2430
   PubMed Web of Science ®Google Scholar
• Das TP, Suman S, Alatassi H, Ankem MK, Damodaran C. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer. Cell Death Dis 2016; 7:e2111; PMID:26913603; http://dx.doi.org/10.1038/cddis.2015.403
   PubMed Web of Science ®Google Scholar
• Chen X, Sahasrabuddhe AA, Szankasi P, Chung F, Basrur V, Rangnekar VM, Pagano M, Lim MS, Elenitoba-Johnson KS. Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival. Cell Death Differ 2014; 21:1535-45; PMID:24992930; http://dx.doi.org/10.1038/cdd.2014.92
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bao M, Lu N, Weng L, Yuan B, Liu YJ. The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat Immunol 2013; 14:172-8; PMID:23222971; http://dx.doi.org/10.1038/ni.2492
   PubMed Web of Science ®Google Scholar
• Lazzari E, Korczeniewska J, Ni Gabhann J, Smith S, Barnes BJ, Jefferies CA. TRIpartite motif 21 (TRIM21) differentially regulates the stability of interferon regulatory factor 5 (IRF5) isoforms. PloS one 2014; 9:e103609; PMID:25084355; http://dx.doi.org/10.1371/journal.pone.0103609
   PubMed Web of Science ®Google Scholar
• Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol 2008; 181:1780-6; PMID:18641315; http://dx.doi.org/10.4049/jimmunol.181.3.1780
   PubMed Web of Science ®Google Scholar
• Jauharoh SN, Saegusa J, Sugimoto T, Ardianto B, Kasagi S, Sugiyama D, Kurimoto C, Tokuno O, Nakamachi Y, Kumagai S, et al. SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production. Biochem Biophys Res Commun 2012; 417:582-7; PMID:22178074; http://dx.doi.org/10.1016/j.bbrc.2011.12.010
   PubMed Web of Science ®Google Scholar
• Shibata N, Ohoka N, Sugaki Y, Onodera C, Inoue M, Sakuraba Y, Takakura D, Hashii N, Kawasaki N, Gondo Y, et al. Degradation of stop codon read-through mutant proteins via the ubiquitin-proteasome system causes hereditary disorders. J Biol Chem 2015; 290:28428-37; PMID:26442586; http://dx.doi.org/10.1074/jbc.M115.670901
   PubMed Web of Science ®Google Scholar
• Espinosa A, Zhou W, Ek M, Hedlund M, Brauner S, Popovic K, Horvath L, Wallerskog T, Oukka M, Nyberg F, et al. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 2006; 176:6277-85; PMID:16670339; http://dx.doi.org/10.4049/jimmunol.176.10.6277
   PubMed Web of Science ®Google Scholar
• Ding Q, He D, He K, Zhang Q, Tang M, Dai J, Lv H, Wang X, Xiang G, Yu H. Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers. Tumour Biol 2015; 36:8761-72; PMID:26055142; http://dx.doi.org/10.1007/s13277-015-3572-2
   PubMed Web of Science ®Google Scholar
• Brauner S, Zhou W, Backlin C, Green TM, Folkersen L, Ivanchenko M, Lofstrom B, Xu-Monette ZY, Young KH, Moller Pedersen L, et al. Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B cell lymphoma patients with and without rheumatic disease. J Intern Med 2015; 278:323-32; PMID:25880119; http://dx.doi.org/10.1111/joim.12375
   PubMed Web of Science ®Google Scholar
• Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 2012; 39:77-82; PMID:22402340; http://dx.doi.org/10.1016/j.jaut.2012.01.014
   PubMed Web of Science ®Google Scholar
• Chaudhry P, Singh M, Parent S, Asselin E. Prostate apoptosis response 4 (Par-4), a novel substrate of caspase-3 during apoptosis activation. Mol Cell Biol 2012; 32:826-39; PMID:22184067; http://dx.doi.org/10.1128/MCB.06321-11
   PubMed Web of Science ®Google Scholar
• Tan J, You Y, Xu T, Yu P, Wu D, Deng H, Zhang Y, Bie P. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. Toxicol Lett 2013; 224:7-15; PMID:24144893; http://dx.doi.org/10.1016/j.toxlet.2013.10.008
   PubMed Web of Science ®Google Scholar
• Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH, Rangnekar VM. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 1999; 18:1205-8; PMID:10022126; http://dx.doi.org/10.1038/sj.onc.1202416
   PubMed Web of Science ®Google Scholar
• Joshi J, Fernandez-Marcos PJ, Galvez A, Amanchy R, Linares JF, Duran A, Pathrose P, Leitges M, Canamero M, Collado M, et al. Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J 2008; 27:2181-93; PMID:18650932; http://dx.doi.org/10.1038/emboj.2008.149
   PubMed Web of Science ®Google Scholar
• Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M, et al. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 2007; 67:1927-34; PMID:17332319; http://dx.doi.org/10.1158/0008-5472.CAN-06-2687
   PubMed Web of Science ®Google Scholar
• Lee TJ, Lee JT, Kim SH, Choi YH, Song KS, Park JW, Kwon TK. Overexpression of Par-4 enhances thapsigargin-induced apoptosis via down-regulation of XIAP and inactivation of Akt in human renal cancer cells. J Cell Biochem 2008; 103:358-68; PMID:18041764; http://dx.doi.org/10.1002/jcb.21642
   PubMed Web of Science ®Google Scholar
• Brasseur K, Fabi F, Adam P, Parent S, Lessard L, Asselin E. Post-translational regulation of the cleaved fragment of Par-4 in ovarian and endometrial cancer cells. Oncotarget 2016; 7:36971-87; PMID:27175591; http://dx.doi.org/10.18632/oncotarget.9235
   PubMed Web of Science ®Google Scholar
• El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 2003; 23:5516-25; PMID:12897127; http://dx.doi.org/10.1128/MCB.23.16.5516-5525.2003
   PubMed Web of Science ®Google Scholar
• Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol 2016; 77:1103-24; PMID:26886018; http://dx.doi.org/10.1007/s00280-016-2976-z
   PubMed Web of Science ®Google Scholar
• Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9:671-5; PMID:22930834; http://dx.doi.org/10.1038/nmeth.2089
   PubMed Web of Science ®Google Scholar